NUVB as reported
Nuvation Bio Inc. reported $143M of revenue over the trailing twelve months, +1206% on the year before. 10 reported series are charted on this page, each one as filed.
$143M
Revenue, trailing twelve months · to Q1 2026 · +1206% against the twelve months before
- Net Income
- −$146M
Net Income · −76% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$223M
Free Cash Flow · +41% year on year · trailing twelve months to Q1 2026
- Op Margin
- −456%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $143M | +1206% | Q1 2026 |
| Net Income | −$146M | −76% | Q1 2026 |
| EPS | −$0.43 | −80% | Q1 2026 |
| Gross Margin | 45% | n/a | Q3 2025 |
| Op Margin | −456% | n/a | Q1 2026 |
| Net Margin | −432% | n/a | Q1 2026 |
| ROE | −58% | n/a | Q1 2026 |
| ROA | −31% | n/a | Q1 2026 |
| ROIC | 94% | n/a | Q1 2026 |
| Free Cash Flow | −$223M | +41% | Q1 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Nuvation Bio Inc. (NUVB) - Revenue & ProfitRevenue & ProfitNuvation Bio Inc. (NUVB)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com